Significant Agreements - Narratives (Details) $ / shares in Units, $ in Thousands				1 Months Ended				3 Months Ended			12 Months Ended
	Mar. 01, 2023 item	Jan. 08, 2023 $ / shares	Mar. 04, 2022 USD ($) item	Oct. 31, 2024 USD ($)	Feb. 28, 2023 USD ($) $ / shares	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($) Program $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2024 USD ($) item	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											$ 80,001	$ 250,008	$ 40,907
2023 Neurocrine Collaborative Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of profit or loss under co-co option		50.00%
Percentage of development costs incurred		50.00%
Novartis Pharma, AG | 2023 Novartis Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment											80,000
Contract expense												1,900
Allocation of Transaction Price
Allocation of fixed consideration											80,000
Costs to obtain collaboration agreement								$ 1,900				$ 1,900
Novartis Pharma, AG | Option and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue				$ 15,000							15,000
Number of targets | item	2		2
Upfront payment			$ 54,000								$ 15,000
Neurocrine | 2019 Neurocrine Collaborative Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of collaboration programs | item											3
Number of discovery programs							2					97,382
Upfront payment							$ 115,000				$ 115,000
Price per share | $ / shares							$ 11.9625
Aggregate maximum milestone payments to be received from collaborative partner							$ 130,000
Estimated cost reimbursement								83,300	$ 81,700	$ 80,000	431,100
Termination period							10 years
Discount related to equity investment											27,600
Equity investment											50,000
Allocation of Transaction Price
Allocation of variable consideration											82,370
Allocation of fixed consideration											92,400
Reimbursement costs expected to be received											$ 400
Consideration received						$ 5,000
Neurocrine | 2023 Neurocrine Collaborative Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of discovery programs | item											3
Number of development and commercialization licenses | item											2
Percentage of profit or loss under co-co option		50.00%
Percentage of development costs incurred		50.00%
Upfront payment					$ 136,000
Price per share | $ / shares		$ 8.88			$ 8.88
Termination period					10 years
Discount related to equity investment					$ 39,000
Allocation of Transaction Price
Allocation of variable consideration											$ 8,984
Allocation of fixed consideration					$ 143,900						149,880
Reimbursement costs expected to be received											$ 9,000
Costs to obtain collaboration agreement								$ 400				$ 400